Hematology

The interventional cardiologist and professor, Duke University School of Medicine, discussed trends of new data on XC001.

NY-ESO-1 TCR/IL-15 NK previously received clearance of an IND for advanced synovial sarcoma and myxoid/round cell liposarcoma in June 2023.

A DSMB futility analysis found that the trial was unlikely to meet its primary composite endpoint and trial enrollment has been paused.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

Review top news and interview highlights from the week ending July 21, 2023.

The assistant professor of microbiology at Penn Medicine discussed further research to be done with EGR2 and type 1 interferon.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The updated report maintains exa-cel's C++ grade and lovo-cel's B+ grade.

Among 16 patients who were treated with Caribou Biosciences’ CB-010, the ORR was 94% and the CR rate was 69%.

The guidance outlines recommendations for managing and reporting CGT manufacturing changes and PMR noncompliance.

The principal investigator at Seattle Children’s Research Institute discussed the continuing need to share preclinical research at conferences even as more gene therapies enter the clinic.

ARUP Laboratories’ AAV5 DetectCDx utilizes electrochemiluminescence to detect antiAAV5 antibodies in samples of patients’ plasma.

The proof-of-concept trial was in healthy volunteers, and additional studies are being planned in patients with blood cancers undergoing hematopoietic stem cell transplants.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The principal investigator at Seattle Children’s Research Institute discussed the potential of new delivery methods and gene editing to overcome the limitations of AAV vector-based gene therapies.

Invimestrocel is being investigated for multiple indications, including ischemic stroke.

Hemogenyx is currently remanufacturing the therapy without the identified splicing issue.

The senior research fellow at Fred Hutch Cancer Center discussed research trends at the 2023 ASGCT meeting.

ACE1831 is Acepodia’s first γδ T-cell therapy to enter clinical trials.

Review top news and interview highlights from the week ending July 7, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The director of therapeutic genome engineering, St. Jude Children’s Research Hospital discussed challenges with performing prime editing in cells.

The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.

Review top news and interview highlights from the week ending June 30, 2023.

The FDA’s decision to approve this first gene therapy in hemophilia A was based on data from the phase 3 GENEr8-1 clinical trial.